secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-09-29T12:01:22+00:00
Accession:  0001664710-26-000059
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Keros to receive $20M Takeda milestone after first patient dosed in Phase 3 ELRiSE MF trial
--------------------------------------------------------------------------------

- Keros expects a $20M development milestone from Takeda after the first patient was dosed in ELRiSE MF, a Phase 3 trial of elritercept vs placebo in myelofibrosis with anemia on ruxolitinib.
- The Takeda license, effective January 16, 2025, covers development, manufacturing, and commercialization of elritercept worldwide excluding mainland China, Hong Kong, and Macau.
- Keros received a $200M upfront cash payment in February 2025 and can earn development, commercial, and sales milestones potentially exceeding $1.1B plus tiered royalties.
- Keros plans to distribute 25% of net cash proceeds from the $20M milestone to stockholders following receipt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000059/0001664710-26-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000059/kros-20260929.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer